FUJIFILM Diosynth Biotechnologies teams with COVID-19 Therapeutics Accelerator

FUJIFILM Diosynth Biotechnologies teams with COVID-19 Therapeutics Accelerator

to reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies

FUJIFILM Diosynth Biotechnologies HILLERØD, Denmark, April 30, 2020 –

FUJIFILM Diosynth Biotechnologies,

a world leading biologics-Contract Development and Manufacturing Organization (CDMO),

today announced that

it will reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator.

The Therapeutics Accelerator

is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.

Currently,

there are no established therapies for the treatment of COVID-19.

To help address the global crisis,

the Therapeutics Accelerator is working to accelerate drug development and

will identify a promising COVID-19 therapeutic candidate based on efficacy and safety data demonstrated in clinical trials.

Advancing research into accessible coronavirus treatments – COVID-19 Therapeutics Accelerator